Pollution Spurs Record Respiratory Drug Sales: ₹1,950 Cr Surge
Overview
Respiratory medicine sales in India soared to a record ₹1,950 crore in December 2025, driven by escalating air pollution and resulting illnesses. Anti-asthma and COPD therapies led the surge, with annual growth rates exceeding 18%. This trend highlights a significant public health challenge and a burgeoning market for respiratory pharmaceuticals.
Stocks Mentioned
Record Sales Driven by Air Quality
Respiratory medicine sales in India breached ₹1,950 crore in December 2025, marking the highest monthly sales ever recorded. This figure represents a 10% increase over December 2024 and a substantial 18% jump compared to 2023.
The data, compiled by market research firm Pharmarack, signals a worrying escalation in pollution-linked respiratory ailments across urban centers.
Therapeutic Breakdown and Key Drugs
For the critical October-December quarter, a period notorious for peak pollution levels, respiratory therapy sales climbed 14% year-on-year over 2024 and 8% over 2023. Total sales for the quarter reached ₹5,620 crore, a 17% rise from the previous quarter.
Anti-asthma and Chronic Obstructive Pulmonary Disease (COPD) medications accounted for the majority of this revenue, contributing nearly ₹3,500 crore. Drugs like Foracort, used for asthma and respiratory issues, were among the top sellers, mirroring the seasonal demand surge.
Expert Views on Health Impact
Medical experts attribute the sharp rise in sales to aggravated asthma, respiratory infections, and the onset of serious conditions like COPD due to exposure to toxic air. Dr. Amitabh Malik of Paras Health noted a 60% increase in patients with allergic rhinitis and bronchitis during peak pollution periods.
While masks and air purifiers offer some protection, steroid inhalers and anti-allergy medications form the core of treatment. Pharmaceutical companies like GSK Pharma India observe a typical seasonal uptick in respiratory infections from October to February, exacerbated by poor air quality, leading to increased demand for related medications.
